Conference Proceedings
Discontinuation of nucleot(s)ide analogue therapy in HBeAg-negative chronic hepatitis B: a meta-analysis
SAL Hall, S Vogrin, O Wawryk, GS Burns, K Visvanathan, V Sundararajan, A Thompson
Gut | BMJ PUBLISHING GROUP | Published : 2022
Abstract
background and aims Sustained virological suppression and hepatitis B surface antigen (HBsAg) loss have been described after nucleot(s)ide analogue (NA) discontinuation for patients with hepatitis B e antigen (HBeAg)-negative chronic hepatitis B (CHB). We performed a meta-analysis of the clinical outcomes after NA discontinuation for HBeAg-negative CHB. Methods Studies involving NA cessation in HBeAg-negative CHB individuals with a median follow-up of ≥12 months were included. Participants were HBeAg-negative at the time of NA initiation. Random effects meta-analyses were performed for the following clinical outcomes: (1) virological relapse (VR) at 6 and 12 months; (2) clinical relapse (CR)..
View full abstractGrants
Awarded by National Health and Medical Research Council
Funding Acknowledgements
AT received funding from the National Health and Medical Research Council of Australia (MRFF Practitioner Fellowship 1142976). This work was supported by NHMRC Project Grant 1066536.